Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: Abstracts from the 17th International Symposium on HIV and Emerging Infectious Diseases (ISHEID)

Open Access Oral presentation

Search for small molecule activators of latent HIV

Romas Geleziunas*, George Stepan, George Wei, Helen Yu, Michael Graupe, Nikos Pagratis, Tiffany Barnes, Tomas Cihlar and Joe Hesselgesser

Author Affiliations

Clinical Virology at Gilead Sciences, Inc., Foster City, USA

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 1):O2  doi:10.1186/1742-4690-9-S1-O2

The electronic version of this article is the complete one and can be found online at:

Published:25 May 2012

© 2012 Geleziunas et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral presentation

Reservoirs of HIV that persist during ART represent barriers to eradication of this virus. One well documented reservoir of latent HIV is found in memory CD4+ T-cells. Identifying means to safely eliminate latently infected memory CD4+ T-cells is an important goal that may contribute to a cure for HIV. One approach toward this end is to activate latent proviruses with the premise that viral particles emanating from these cells will cause a cytopathic effect leading to the demise of the host cell. We have optimized and automated a primary cell-based HIV latency assay that can be used for high throughput screening of small molecule libraries in search of HIV activators. Using this assay, we have identified novel histone deacetylase (HDAC) inhibitors fromGilead’s compound collection that activate latent HIV. Analysis of these inhibitors revealed that the magnitude of HIV expression correlated with the breadth of cellular HDAC inhibition. In addition, we have identified a variety of other compounds that activate latent HIV such as kinase inhibitors which may point to novel mechanisms that govern HIV latency. This screening assay has the potential to identify novel molecular targets for drug discovery and new chemical classes that could be optimized to create new drugs to eliminate reservoirs of latent HIV.